Peptide CDMO (Pharmaceutical) Market will Grow at a CAGR of 9.0% from 2023 to 2031

Feb 20, 2024

Companies covered in this study are AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL- Chemical and Biopharmaceutical Laboratories, Creative Peptides, Chinese Peptide, CSBio, Corden Pharma

Jersey City, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " “Global Peptide CDMO (Pharmaceutical) Market Trends, Industry Competition Analysis, Company Profiles, Revenue Estimates and Forecast To 2030."

According to the latest market research report, the global peptide CDMO (pharmaceutical) market is valued at US$ 2028.60 million in 2021, and it is expected to reach US$ 4321.26 million by 2030, with a CAGR of 9.0% during the forecast period of 2022-2030. By region, Asia Pacific dominated the market with a market share of 42.4% in 2021.

Peptides are small protein molecules that contain fewer amino acids compared to proteins. Peptide therapeutics play an essential role in addressing unmet medical needs. Several peptide drugs have reached the market for treating different diseases, including cancer, diabetes, osteoporosis, chronic pain, multiple sclerosis, and HIV infection. Peptide CDMO is considered an emerging market due to its excellent peptide therapeutic properties and promising potential for the contract API manufacturing industry.

Free PDF Report Brochure @ https://www.insightaceanalytic.com/request-sample/1202

Factors such as the developing healthcare infrastructure, increasing medical applications of peptides, rising healthcare expenditures, emerging peptide design technologies, growing usage of peptides for drug development, rising R&D investments for peptide-based therapies, high prevalence of chronic diseases, and the use of bioinformatics and systematic biological approaches for peptide designing are predicted to drive the peptide CDMO (pharmaceutical) market during the forecast years.

The high prevalence of chronic and infectious diseases leads to increased drug demands. Hence, pharmaceutical companies began to opt for peptides and CDMOs services to manage the product manufacturing burden. Peptides are used due to their high specificity, tolerability, and ease of manufacturing, and contract manufacturing services save time and enhance production efficiency. Likely to surge the business growth opportunities for the peptide CDMO (pharmaceutical) market over the projected period.

However, factors such as the expensive CDMOs services and the need for specialized expertise for peptide production are estimated to impede the market development over the estimated timeframe.

Regionally, North America, followed by Europe, is projected to lead the peptide CDMO (pharmaceutical) market during the forecast period (2022-2030), owing to the well-developing CDMOs, availability of peptide synthesis technologies, and the surging demand for peptides and drugs to treat chronic conditions.

Key developments in the market:

In January 2022, CordenPharma collaborated with PeptiSystems, a Swedish-based developer of peptide and oligonucleotide therapeutic process development and manufacturing instruments, to reduce the footprint impact and improve the Process Mass Intensity (PMI) of peptide manufacturing processes.

In December 2021, Pepscan extended its column purification technology with a mid-sized column packer. This technology significantly reduces purification time and provides optimal flexibility when synthesizing peptides.

In September 2021, CEM Corporation and AmbioPharm, Inc. partnered to produce GMP peptides for the global market. The partnership will involve an exclusive1 use of CEM’s large-scale microwave peptide synthesis technology to produce GMP peptides up to multi-kilogram quantities using proprietary scalable reactors. Also, it will enable rapid and efficient production of peptide new chemical entities (NCE’s) using the latest technologies available.

In July 2021, CordenPharma expanded its peptide manufacturing capacity in CordenPharma Colorado, their GMP API facility in Boulder, CO (US). CordenPharma Colorado is the largest worldwide peptide API producer leading the global peptide market.

Key market players operating in the peptide CDMO (pharmaceutical) market include:

AmbioPharm,

Auspep,

Bachem,

BCN Peptide,

CPC Scientific,

CBL- Chemical and Biopharmaceutical Laboratories,

Creative Peptides,

Chinese Peptide,

CSBio,

Corden Pharma,

PolyPeptide,

Hybio Pharmaceutical,

Peptide Institute,

Pepscan,

Almac,

Vivitide,

CreoSalus Inc,

ScinoPharm,

Senn Chemicals,

Wuxi AppTec,

Olon,

Belyntic,

Ferring Pharma,

Numaferm,

Hybio Pharmaceutical,

Provepharm Life Solutions,

Enzene Biosciences,

Ardena Holding,

Stelis Biopharma,

Piramal Pharma,

Space Peptides Pharmaceutical

Get Customized Report @ https://www.insightaceanalytic.com/customisation/1202

Peptide CDMO (Pharmaceutical) Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 2173.44 Million

Revenue Forecast In 2031

USD 4784.50 Million

Growth Rate CAGR

CAGR of 9.3 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Scale of Operation, Method Used, Applications, Synthesis Types,

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Market Segments:

Global Peptide CDMO (Pharmaceutical) Market, by Scale of Operation, 2022-2030 (Value US$ Mn)

Preclinical / Clinical

Commercial

Global Peptide CDMO (Pharmaceutical) Market, by Method Used, 2022-2030 (Value US$ Mn)

Chemical Synthesis Method

Non-Chemical Synthesis Method

Global Peptide CDMO (Pharmaceutical) Market, by By Applications, 2022-2030 (Value US$ Mn)

Peptide Supplements

Peptide Vaccines

Peptides as Radio-Theranostic Agents

Cell Penetrating Peptides (CPPs)

Affinity Ligands

Protein Mimics

Global Peptide CDMO (Pharmaceutical) Market, by Synthesis Types, 2022-2030 (Value US$ Mn)

LPPS

SPPS

Mixed Phase

Global Peptide CDMO (Pharmaceutical) Market, by Region, 2022-2030 (Value US$ Mn)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Enquiry Before Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1202

North America Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

The U.S.

Canada

Europe Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

Germany

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

India

China

Japan

South Korea

Australia & New Zealand

Latin America Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

Brazil

Mexico

Rest of Latin America

The Middle East & Africa Peptide CDMO (Pharmaceutical) Market, by Country, 2022-2030 (Value US$ Mn)

GCC Countries

South Africa

Rest of the Middle East & Africa

About Us:

InsighAce Analytic is a specializing in market research and consulting services that helps in building business strategies. Our mission is to provide high quality insights with using data analytics techniques and visualization tools that drives the disruption and innovation in market research industry. Our expertise is in providing syndicated and custom market intelligence reports with in-depth analysis and key market insights in a timely and cost-effective manner.

Follow Us @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Subscribe Our Exclusive Newsletters @ https://www.linkedin.com/newsletters/latest-market-research-reports-6929319878155739136/